TNGX
Tango Therapeutics·NASDAQ
--
--(--)
Market Open: --
--
--(--)
Pre-Market: --
Signals Analysis
Bullish signal 4
Bearish signal 1
Consensus Rating "Strong Buy"
Ample Liquidity
High Gross Profit Margin
EPS Beats Expectation
Revenue Below Expectations
Key Stats
0.0000DAY`S RANGE0.0000
0.000052 WK RANGE0.0000
0.0000
0.0000
--
--
--
--
--
--
--
--
--
--
--
--
--
--
0.0000
0.0000
0.0000
0.0000
About TNGX
Tango Therapeutics Inc.
A precision oncology company that develops therapeutic novel medicines targeting cancer vulnerbilities
201 Brookline Ave., Suite 901, Boston, MA 02215
--
Tango Therapeutics Inc., incorporated in Delaware on May 21, 2020, is a biotechnology company dedicated to discovering new drug targets and delivering next-generation precision medicine for the treatment of cancer. Tango uses a patient-starting and endpoint approach to discover and develop therapies for key cancer targets using the genetic principle of synthetic lethality. This includes expanding the scope of precise oncology targets into new areas, such as tumor suppressor gene loss and its contribution to the ability of cancer cells to evade immune cell killing.
Company Financials
EPS
TNGX has released its 2025 Q3 earnings. EPS was reported at -0.14, versus the expected -0.07, missing expectations. The chart below visualizes how TNGX has performed over recent quarters, highlighting trends in earnings surprises.
Revenue & Expenses
TNGX has released its 2025 Q3 earnings report, with revenue of 53.81M, reflecting a YoY change of 363.61%, and net profit of 15.88M, showing a YoY change of 154.46%. The Sankey diagram below clearly presents TNGX's revenue sources and cost distribution.
Forecast
Wall Street Opinions
Price Target
Volume Profile
Trade Flow Insight
Seasonals
Community Forum
Loading...
Related News
No articles available
